(Q81.1) Epidermolysis bullosa letalis

More details coming soon

Icon
19 994 in individuals diagnosis epidermolysis bullosa letalis confirmed
Icon
2 440 deaths with diagnosis epidermolysis bullosa letalis
Icon
12% mortality rate associated with the disease epidermolysis bullosa letalis

Diagnosis epidermolysis bullosa letalis is diagnosed Women are 11.98% more likely than Men

8 799

Men receive the diagnosis epidermolysis bullosa letalis

1 212 (13.8 %)

Died from this diagnosis.

100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0
11 195

Women receive the diagnosis epidermolysis bullosa letalis

1 228 (11.0 %)

Died from this diagnosis.

Risk Group for the Disease epidermolysis bullosa letalis - Men aged 0 and Women aged 20-24

Icon
In Men diagnosis is most often set at age 0-34, 40-44, 55-59, 85-89
Icon
Less common in men the disease occurs at Age 35-39, 45-54, 60-84, 90-95+Less common in women the disease occurs at Age 35-44, 50-54, 65-79, 85-95+
Icon
In Women diagnosis is most often set at age 0-34, 45-49, 55-64, 80-84

Disease Features epidermolysis bullosa letalis

Icon
Absence or low individual and public risk
Icon

Epidermolysis bullosa letalis - what does this mean

Epidermolysis bullosa letalis is a rare and severe form of epidermolysis bullosa, a genetic disorder characterized by fragile skin and recurrent blistering. it is caused by a mutation in the gene that codes for the protein type vii collagen, which is essential for skin integrity. this mutation leads to an inability of the skin to maintain its structural integrity, resulting in the formation of blisters and wounds.

What happens during the disease - epidermolysis bullosa letalis

Epidermolysis bullosa letalis is a rare genetic disorder caused by a mutation in the lamb3 gene. this gene mutation leads to a decrease in the production of a protein called laminin-332, which is important for the structure and strength of the epidermis. without this protein, the skin and mucous membranes become fragile and prone to blistering and tearing, leading to severe pain, infection, and scarring. in severe cases, the blisters can be so extensive that they cause life-threatening complications, such as sepsis or organ failure.

Clinical Pattern

Epidermolysis bullosa letalis is a rare and severe type of epidermolysis bullosa, a group of genetic skin blistering disorders. It is characterized by widespread blistering, skin fragility, and skin erosions. It is usually present at birth with widespread blistering on the skin, mucous membranes, and internal organs. It is often accompanied by malnutrition, anemia, and growth and developmental delay. This condition is fatal in infancy and early childhood due to complications from skin fragility and malnutrition.

How does a doctor diagnose

  • Complete physical examination
  • Skin biopsy
  • Genetic testing
  • Blood tests to check for inflammation
  • X-ray imaging of the affected area
  • Ultrasound imaging of the affected area
  • CT scan of the affected area
  • MRI of the affected area
Additions:
  • Electron microscopy
  • Immunofluorescence studies

Treatment and Medical Assistance

Main goal of the treatment: To reduce the severity of the symptoms and improve quality of life for those affected by epidermolysis bullosa letalis.
  • Pain management
  • Preventing infection
  • Promoting wound healing
  • Prescribing nutritional supplements
  • Regular skin care and moisturizing
  • Providing emotional support
  • Physical therapy
  • Prescribing antibiotics and antiviral medications
  • Surgery to remove scar tissue and reduce the risk of infection
  • Using topical creams and ointments to reduce itching and inflammation
Icon
17 Days of Hospitalization Required
Icon
Average Time for Outpatient Care Not Established

Epidermolysis bullosa letalis - Prevention

Epidermolysis bullosa letalis is a rare genetic disorder that is typically fatal in infancy. prevention of this disorder is largely based on genetic counseling for families who have a history of the disorder. genetic testing can be used to identify carriers of the gene, and prenatal testing can be used to identify affected fetuses.